Assessment of Efficacy, Safety of mRNA COVID-19 Vaccines in Children Ages 5 to 11

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11:10 A.M. (ET), MONDAY, JANUARY 23, 2023

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2022.6243?guestAccessKey=e77a8d4a-c5d4-415a-8a30-1b5d4478d31d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012323

 

About The Study: In this systematic review and meta-analysis including 17 studies with 10.9 million vaccinated and 2.6 million unvaccinated children ages 5 to 11, mRNA COVID-19 vaccination was associated with lower risks of SARS-CoV-2 infections, severe COVID-19–related illnesses, and hospitalizations due to COVID-19. While vaccination, compared with placebo, was associated with higher incidences of adverse events, the overall frequency of severe adverse events was low.  

Authors: Jun Yasuhara, M.D., of Nationwide Children’s Hospital in Columbus, Ohio, and Toshiki Kuno, M.D., Ph.D., of the Albert Einstein College of Medicine in New York, are the corresponding authors.

 

(doi:10.1001/jamapediatrics.2022.6243)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.